Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG Reaffirms FY 2012 Operating Loss Guidance-Conference Call
Basilea Pharmaceutica AG announced that it has not changed guidance and expects operating loss, which is similar to the cash burn, is around CHF6 million or CHF7 million per month for fiscal 2012.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG Announces Isavuconazole Orphan Drug Designation For Treatment Of zygomycosis By U.S.
- Basilea Pharmaceutica AG And Astellas Pharma Inc Reports Positive Topline Phase 3 Results For Antifungal Isavuconazole
- Basilea Pharmaceutica AG Announces Isavuconazole Orphan Drug Designation By U.S. FDA
- Basilea Pharmaceutica AG's Board Proposes Martin Nicklasson To Succeed Chairman Werner Henrich
Latest Key Developments in Pharmaceuticals
- Bristol-Myers Squibb Co announces four-year data from Phase 3 DASISION trial comparing Sprycel (dasatinib) to Imatinib in first-line treatment of adults with Ph+ CP-CML
- Endo Health Solutions Inc's American Medical Systems receives FDA 510(k) clearance of RetroArc Retropubic Sling System for treatment of female stress urinary incontinence
- Swedish Orphan Biovitrum publ AB and Biogen Idec Inc announce results of phase 3 study of recombinant factor IX and VIII Fc fusion protein candidates
- Coronado Biosciences Inc announces IND submission for TSO for the treatment of Moderate to Severe Chronic Plaque Psoriasis
- Share this
- Digg this